Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes
Authors' conclusion
In older individuals, higher AT1RaAb levels were associated with inflammation, hypertension, and adverse outcomes.
Study context
- Population
- Community-dwelling older adults
- Participants
- 255 vs 60
- Comparison
- Higher vs lower AT1RaAb levels
- Baltimoren = 255
- Chicagon = 60
- Outcome
- Associations of AT1RaAbs with physical function tests and outcomes
Methodological detailsdiscovery cohort (Baltimore), validation cohort (Chicago)
- Discovery cohort (Baltimore)
- Validation cohort (Chicago)
Performance
As reported in the abstract
- Baltimore: AT1RaAbs vs interleukin-6, Spearman r=0.33
- P<0.0001
- Baltimore: AT1RaAbs vs SBP, Spearman r=0.28
- P<0.0001
- Baltimore: AT1RaAbs vs BMI, Spearman r=0.28
- P<0.0001
- Baltimore: AT1RaAbs vs weaker grip strength, Spearman r=−0.34
- P<0.01
- Baltimore: AT1RaAbs vs slower walking speed, Spearman r=−0.30
- P<0.05
- Baltimore: high AT1RaAbs, likelihood of high risk (age-adjusted), 3.9 times (95% CI 1.38-11.0)
- P<0.05
- Baltimore: odds of falling per 1 µg/mL increase in AT1RaAbs (adjusted for age, sex, BMI, BP)
- 30% increase
- Chicago: AT1RaAbs vs grip strength, Spearman r=−0.57
- P<0.005
- Chicago: AT1RaAbs vs walking speed, Spearman r=−0.47
- P<0.005
- Chicago: AT1RaAbs vs falls, Spearman r=0.30
- P<0.05
- Chicago: time to death per 1 µg/mL increase in AT1RaAbs (adjusted for age, sex, BMI, BP)
- 9% decrease
Further findings
Chronic ARB treatment (Chicago)
- Chronic ARB treatment associated with better SBP control and attenuation of decline in grip strength and time to death
Original publication
Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes. Circulation. Published 30 November 2016. doi:10.
Summarised from the published abstract; every number is checked against it